美國居民不適用 XM 服務。
R
R

Roche

技術摘要

指標價值趨勢
指標價值趨勢
指標價值趨勢
指標S3S2S1PR1R2R3

財經新聞

Financial Times - Oct 1

PRESS DIGEST- Financial Times - Oct 1 Oct 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Simon Case steps down as UK cabinet secretary - EY picks Anna Anthony as UK boss after three-way race - Roche plans to launch drugs and slash development costs - LVMH sells Off-White streetwear brand founded by Virgil Abloh - Qatar Airways agrees to buy 25% stake in Virgin Australia Overview Sim
L
R

Roche targets more than $3 billion in annual obesity sales

UPDATE 1-Roche targets more than $3 billion in annual obesity sales Releads By Ludwig Burger FRANKFURT, Sept 30 (Reuters) - Roche ROG.S said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales . In a presentation to investors, the Swiss drugmaker said the revenue projection applies on aggregate to weekly injection CT-388 - which is similar t
R

Roche aims to slash drug development time and costs by 2030

Roche aims to slash drug development time and costs by 2030 FRANKFURT, Sept 30 (Reuters) - Swiss drugmaker Roche ROG.S said on Monday it aims to slash the development costs of drugs it brings to market and speed up their development time by 2030. Average development costs of a drug that is launched should decline by 20% and the time from early drug discovery to the end of Phase 3 testing on humans would be cut by 40%, according to presentation slides posted on the company's website.
R

Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - Roche Holding AG ROG.S : POSITIVE PHASE III RESULTS FOR GENENTECH’S GAZYVA SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS Source text for Eikon: ID:nBw2HSqmRa Further co
R

Vontobel raises Roche to 'buy' ahead of expected strategy update

BUZZ-Vontobel raises Roche to 'buy' ahead of expected strategy update ** Vontobel raises Roche ROG.S to "buy" from "hold" based on the Swiss drugmaker's planned R&D cost controls and ahead of its expected strategy update at the end of the month ** The company's Pharma Day on Sept. 30 is the key event to understanding how the new leadership will run
R

細節

熱門資產

免責聲明: XM Group提供線上交易平台的登入和執行服務,允許個人查看和/或使用網站所提供的內容,但不進行任何更改或擴展其服務和訪問權限,並受以下條款與條例約束:(i)條款與條例;(ii)風險提示;(iii)完全免責聲明。網站內部所提供的所有資訊,僅限於一般資訊用途。請注意,我們所有的線上交易平台內容並不構成,也不被視為進入金融市場交易的邀約或邀請 。金融市場交易會對您的投資帶來重大風險。

所有缐上交易平台所發佈的資料,僅適用於教育/資訊類用途,不包含也不應被視爲適用於金融、投資稅或交易相關諮詢和建議,或是交易價格紀錄,或是任何金融商品或非應邀途徑的金融相關優惠的交易邀約或邀請。

本網站的所有XM和第三方所提供的内容,包括意見、新聞、研究、分析、價格其他資訊和第三方網站鏈接,皆爲‘按原狀’,並作爲一般市場評論所提供,而非投資建議。請理解和接受,所有被歸類為投資研究範圍的相關内容,並非爲了促進投資研究獨立性,而根據法律要求所編寫,而是被視爲符合營銷傳播相關法律與法規所編寫的内容。請確保您已詳讀並完全理解我們的非獨立投資研究提示和風險提示資訊,相關詳情請點擊 這裡查看。

風險提示:您的資金存在風險。槓桿商品並不適合所有客戶。請詳細閱讀我們的風險聲明